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Lymphocyte signalling: A coordinating role for Vav?
Doreen Cantrell
Vav1 is a guanine nucleotide exchange factor that
selectively activates the Rac1 GTPase and is expressed
specifically in haematopoietic cells. Recent work has
revealed how Vav1 integrates signals from lymphocyte
antigen receptors and costimulatory receptors to
control immune function.
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GTPases function as binary switches by cycling between
an active, GTP-bound state and an inactive, GDP-bound
state. In their GTP-bound state, these proteins interact
with specific effectors to initiate downstream signal trans-
duction pathways. Guanine nucleotide exchange factors
(GEFs) promote the transition from the inactive GDP-
bound state to the active GTP-bound conformation. Vav
proteins are GEFs which show selectivity for the Rho
family GTPase Rac1. Two closely related Vav proteins
have been identified, Vav1 and Vav2. These molecules
have a Dbl homology region, which marks the catalytic
domain of GEFs specific for Rho GTPases, and contain
one Src homology 2 (SH2) domain and two SH3 domains;
SH2 domains bind to tyrosine-phosphorylated proteins,
and SH3 domains bind to proline-rich peptides. The GEF
activity of Vav1 is upregulated by tyrosine phosphoryla-
tion mediated by coexpression of Src family kinases [1,2].
Vav1 is expressed exclusively in haematopoietic cells and,
in a physiological context, Vav1 is an immediate substrate
for tyrosine kinases following activation of B cells, T cells
and mast cells (for review, see [3]). Significantly, engage-
ment of CD28 — the costimulatory receptor for the T-cell
receptor — with its physiological ligands, B7-1 and B7-2,
can induce a rapid and sustained tyrosine phosphorylation
of Vav1 in T cells in the absence of simultaneous engage-
ment of the T-cell receptor [4]. Vav1 is thus activated by
the initial contact between T cells and antigen-presenting
cells mediated by CD28–B7 interactions [5]. 
The catalytic Dbl domain in Vav1 is flanked carboxy-ter-
minally by a pleckstrin homology (PH) domain that can
bind polyphosphoinositides [6]. It is thought that binding
of these lipids to PH domains of GEFs either allosterically
modifies GEF activity, or facilitates activation of the GEF
by inducing its relocalisation to specific subcellular loca-
tions or defined areas of the plasma membrane where acti-
vation can occur. Activation of the phospholipid kinase
phosphatidylinositol (PI) 3-kinase and the consequent 
elevation of intracellular levels of D-3 phosphoinositides
is a common response to triggering of antigen receptors,
costimulatory receptors and cytokine receptors. The PH
domain of Vav1 binds in vitro to PI 3,4,5-triphosphate, a
product of the reaction catalysed by PI 3-kinase, and this
promotes phosphorylation of Vav1 by tyrosine kinases
thereby activating Vav1’s catalytic function [6]. Binding of
lipid products of the reaction catalysed by PI 3-kinase to
the PH domains of Vav1 may also induce relocalisation of
the protein to specific cellular locations where activation
can occur. 
Other mechanisms that regulate the localisation of Vav1
have also been described. A protein complex between
Vav1 and the adaptor protein SLP-76 is formed in
response to antigen receptor stimulation in T cells [5].
Vav1 also binds via its SH2 domain to the tyrosine kinase
ZAP-70 [7]. These interactions target Vav1 into activated
T-cell receptor complexes. In B cells, CD19 is the co-
receptor that amplifies antigen receptor function. Coliga-
tion of CD19 with the B-cell receptor results in the
tyrosine phosphorylation of CD19 on a high affinity
docking site for the SH2 domain of Vav1 [8], leading to
the subsequent recruitment of Vav1 to CD19. In bio-
chemical terms, Vav1 integrates signals from antigen
receptors and costimulatory molecules and is colocalised
with these receptor complexes during lymphocyte activa-
tion (Figure 1). 
The role of Vav1 in lymphocytes
The above biochemical studies of Vav1 predicted that this
molecule has an important role in lymphocytes and this
was confirmed by analyses of Vav1-deficient mice. These
animals display various defects in T-cell and B-cell devel-
opment. Processes that shape the T-cell repertoire are
defective in Vav1-deficient mice, with T-cell selection
events in the thymus being affected as well as the produc-
tion of peripheral T cells [9]. Moreover, peripheral T lym-
phocytes in Vav1-deficient mice fail to proliferate in
response to antigen-receptor engagement [10,11]. The
molecular basis for this proliferative defect is a failure of
Vav1-deficient T cells to produce the T-cell growth factor
interleukin-2 (IL-2). A role for Vav1 in the induction of
cytokine genes is also revealed by experiments performed
in cultured T-cell lines. Overexpression of Vav1 was
found to dramatically potentiate antigen-mediated tran-
scriptional activation of nuclear factor of activated T cells
(NFAT) [12], a family of molecules that control antigen-
receptor-induced activation of genes for cytokines such as
IL-2, IL-4, granulocyte macrophage colony-stimulating
factor or tumour necrosis factor α. The key question has
been, how does Vav1 impinge on the intracellular sig-
nalling networks that control lymphocyte function? 
Vav1 regulates intracellular calcium levels in T cells and 
B cells
The immediate consequence of antigen receptor ligation
is the activation of tyrosine kinases; Lck, Fyn and ZAP-70
in T cells, and Lyn and Syk in B cells and mast cells. One
role for these tyrosine kinases is to couple antigen recep-
tors to phospholipase Cγ1 or phospholipase Cγ2 which
control the hydrolysis of the inositol lipid PI 4,5-bisphos-
phate (PIP2) thereby generating inositol 1,4,5-trisphos-
phate (IP3) and diacylglycerols, which regulate
intracellular calcium and protein kinase C, respectively. In
Vav1-deficient lymphocytes, there are apparently no prob-
lems with the activation of tyrosine kinases. However,
Vav1-deficient T cells fail to sustain elevated levels of
intracellular calcium in response to antigen receptor stim-
ulation [9–11]. There are also significant problems with
calcium homeostasis in Vav1-deficient B cells following
engagement of antigen receptors and CD19 [8].
The molecular basis for the defects in calcium signalling
in Vav1-deficient B cells has been analysed in detail and
has been shown to result from impaired inositol lipid
biosynthesis [8]. Coligation of the B-cell coreceptor
CD19 with antigen receptors normally results in activa-
tion of PI 4-phosphate (PIP) 5-kinase [8], which phos-
phorylates PIP thus generating PIP2, the substrate for
phospholipase C and the essential precursor for the pro-
duction of IP3 which regulates intracellular calcium. The
activation of PIP 5-kinase is absolutely required for the
continued biosynthesis of PIP2 and the sustained produc-
tion of IP3. O’Rourke et al. [8] found that Vav1 provides
the link between CD19 and PIP 5-kinase. CD19 recruits
Vav1 to the plasma membrane for activation and Rac1,
the main target for Vav1 in lymphocytes, can bind to PIP
5-kinase and stimulate its activity. Hence, the failure of
Vav1-deficient lymphocytes to maintain calcium signals
in response to antigen receptor and CD19 coligation is
attributable to the inability to regulate inositol lipid
biosynthesis via Vav1 and Rac1. A similar analysis of inos-
itol phospholipid metabolism in Vav1-deficient T cells
has not yet been performed. Nevertheless, activation of
PIP 5-kinases is certainly essential for the sustained
hydrolysis of inositol phospholipids in T lymphocytes
and it would seem likely that the model for Vav1 and
Rac1 regulation of calcium that has been established in B
cells is also applicable to T lymphocytes.
Vav1 regulates the actin cytoskeleton in lymphocytes
Overexpression of Vav1 in fibroblasts induces a dynamic
reorganisation of the actin cytoskeleton and the assembly
of integrin signalling complexes [13]. Vav1 has been
shown to initiate Rac1-mediated formation of lamellipo-
dia and focal complexes and the formation of actin stress
fibres and focal adhesions mediated by the RhoA
GTPase. Consistent with the regulatory effects of Vav1
on Rac1 and on RhoA, severe defects in the regulation of
the actin cytoskeleton occur in Vav1-deficient lympho-
cytes [10,11]. At present it is not clear how Vav1 and Rac1
regulate the actin cytoskeleton, but the role of these mol-
ecules in controlling cellular levels of PIP2 and calcium
could be relevant because of the established links
between these processes and the assembly of actin struc-
tures. However, a variety of Rac1 effectors including the
p21-activated kinase (Pak) family of serine/threonine
kinases, mixed lineage kinase (MLK) 2,3, the tyrosine
kinase p120Ack, POR1 (partner of Rac1), and the mitogen-
activated protein kinase kinase kinase Mekk1,4 have
been identified. Vav1, and hence Rac1, therefore have the
potential to regulate diverse cellular responses because
they can couple to multiple effector pathways (Figure 2).
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Figure 1
Vav1 integrates signals from the T-cell receptor (TCR) and CD28.
Tyrosine phosphorylation of Vav stimulates its Rac1 GEF activity. The
tyrosine kinases that phosphorylate Vav1, such as Lck, Fyn and ZAP-70,
can be activated by the TCR and CD28; TCR triggering induces
transient tyrosine phosphorylation of Vav whereas CD28 stimulation
leads to stable Vav phosphorylation mediated by Lck (denoted by the
asterisk). The interaction between Vav1 and membrane-localised
tyrosine kinases is facilitated by the binding of the inositol lipid PIP3 to
the PH domain of Vav1. This inositol lipid is produced by TCR and
CD28 costimulation. The colocalisation of Vav1 with activated tyrosine
kinases is also promoted by interactions between Vav1 and the adaptor
protein SLP76. A Vav1–ZAP-70 protein complex has also been des-
cribed in activated T cells which may recruit Vav1 into activated TCR
complexes. In B lymphocytes, there is a similar model for Vav1
regulation but with the costimulatory molecule CD19 acting as the
crucial link recruiting Vav1 into activated B-cell-receptor complexes.
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The regulation of intracellular calcium and the actin
cytoskeleton by Vav1 may therefore be accomplished by
distinct effector molecules. 
An intact actin cytoskeleton is required for NFAT
transcriptional activity
The importance of the actin cytoskeleton for lymphocyte
responses is already clear. First, sustained triggering of
antigen receptors is dependent on the maintenance of the
actin cytoskeleton. Second, the actin cytoskeleton also
controls the polarisation of T cells towards antigen-pre-
senting cells, a process that is critical for efficient contact
between antigen-presenting cells and T cells and for the
directed release of cytokines and other effector molecules.
Disruption of the contacts between antigen-presenting
cells and T cells would thus indirectly block T-cell signal
transduction. Nevertheless, a striking observation from
recent studies of Vav1 function in lymphocytes is that
there is a more direct role for actin-regulated events in the
transmission of signals that regulate induction of cytokine
genes [11].
The transcription factor NFAT has an essential role in
cytokine gene induction. Activation of NFAT requires the
coordinated interaction of sustained calcium signals and
signalling pathways initiated by Rac1 and another GTPase
Ras. NFAT molecules are cytosolic in quiescent lympho-
cytes and translocate to the nucleus via a calcium–cal-
cineurin-regulated mechanism. In the nucleus, NFAT
molecules form transcriptionally active complexes with
proteins of the activator protein 1 (AP-1) family. Rac1 can
be positioned at two different points in the regulation of
NFAT: first in the antigen-receptor-controlled pathway
that regulates NFAT cellular localisation, and second in
the antigen-receptor-controlled and Ras-mediated path-
ways that control AP-1 expression and function [14,15].
Crabtree and colleagues [11] have now identified a Vav1-
regulated actin-dependent pathway that is required for
NFAT activation. They found that disruption of the actin
cytoskeleton has no impact on the elevation of intracellu-
lar calcium mediated by the antigen receptor, therefore
the requirement for an intact actin cytoskeleton for NFAT
transcriptional activity must be independent of the
calcium signal [11]. Furthermore, NFAT nuclear trans
location apparently occurs normally without Vav1 func-
tion, a surprising finding given the calcium signalling
defects in Vav1-deficient lymphocytes. The actin-regu-
lated signalling pathway controlled by Vav1 thus regulates
the transcriptional activity of NFAT complexes that are
already localised in the nucleus.  
Do Vav1-deficient lymphocytes lose all Rac1 function?
Biochemical quantitation of active Rac1 complexes has
not been carried out in Vav1-deficient lymphocytes, so it
is not known whether these cells have lost all Rac1 func-
tion. The activation of one of the Rac1 effectors, Pak1, is
normal in Vav1-deficient lymphocytes, however, which
raises the possibility that there is residual Rac1 signalling
in Vav1-deficient cells [10]. Moreover, Rac1 function is
required for NFAT nuclear import whereas NFAT
translocation occurs normally in Vav1-deficient lympho-
cytes [11,15]. Vav2, a close relative of Vav1 is ubiquitously
expressed and might compensate for Vav1 loss. Lympho-
cytes also express other Rac1 GEFs, such as Tiam1, which
may be responsible for residual Rac1 signalling in Vav1-
deficient T cells and B cells. If there is compensation for
Vav1 loss, then studies of Vav1-deficient mice will under-
estimate the role of Rac GTPases in lymphocyte biology. 
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Figure 2
Effector function of Vav1 in lymphocytes. Vav1
is a GEF for Rac1 so its function will be
mediated by the Rac1 GTPase. Multiple
effector molecules capable of binding the
activated GTP-bound form of Rac1 have been
described. The spectrum of Rac1 effector
molecules in lymphocytes is yet to be
determined. Current data suggest that Vav1 is
required for the regulation of the actin
cytoskeleton in lymphocytes. The Rac1
effector pathway involved is not known but, by
analogy with fibroblast models, could involve
the molecule POR1 or the kinase Pak. There
is also considerable evidence that Vav1
regulates inositol lipid metabolism, probably
via a PIP 5-kinase.
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In summary, two critical functions for Vav1 in lympho-
cytes have now been identified. The activation of Vav1 by
the coreceptors for the antigen receptors controls inositol
lipid metabolism and sets a threshold that regulates the
calcium responses induced by antigen-receptor signalling
[7]. Vav1 also controls the actin cytoskeleton and allows
antigen receptors to regulate the transcriptional activity of
nuclear localised NFAT [10,11]. These different functions
for Vav1 in lymphocytes demonstrate that Rac1 can regu-
late disparate effector targets. Ultimately, the details of
Vav1 function will be determined by the unique expres-
sion patterns of different Rac1 effector molecules in dis-
tinct cell types.
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